In the USA, rTMS was cleared by the Food and Drug Administration (FDA) in 2008 to treat patients suffering from treatment resistant depression, or in other words, patients who do not respond to standard antidepressants. It has since been approved or recommended in several other countries. The main advantage of rTMS is that it is a non-invasive, drug-free, and safe alternative treatment that really works: up to half of the patients for whom other antidepressant strategies have not worked will respond to rTMS.

What do the terms incidence and prevalence stand for? What do they measure? What are they used for?

Incidence and prevalence are two statistical measures of disease frequency that apply to any and every disease, although here we’ll just be concerned with cancer.

The Champalimaud Foundation and the IAEA are thus starting a partnership for the development of research, treatment and diagnosis of oncological diseases. The collaboration focuses on the areas of radiation oncology, diagnostic medical imaging, nuclear medicine and medical physics.

A study performed by the team of haematologist Cristina João, who leads the Myeloma and Lymphoma Research Group at the Champalimaud Centre for the Unknown, suggests that it may be possible, in a near future, to diagnose and monitor the progression of multiple myeloma (MM) by simply using a blood sample. Their results were published today (21/06/2022) in the journal Frontiers in Oncology.

On June 8th, at 19h00, the Champalimaud Foundation opens the exhibition 'Insight Inside', the latest work by Clo Bourgard, in which the artist questions how our inner world brings us closer to nature and the environment, through pieces of art made exclusively with recycled materials.

Zoom-In on Champalimaud: Justyna Kociolek

Metaplasia, dysplasia, neoplasia are three processes of cellular transformation.

Metaplasia occurs when a type of cell transforms itself into another normal cell type, as an adaptive response to adverse environmental conditions (for example, inflamation).

A woman who’s just had one of her breasts entirely removed, which forever leaves her with a huge scar across half of her chest, might be very satisfied with the result. If this was her only option, what obviously most matters to her is to be rid of the disease. But for another, who has submitted to a more advanced breast surgery – that is equally successful in clinical terms, but also more conservative and reconstructive – might on the other hand find her new look highly unsatisfactory in spite of the aesthetic results of the surgery being flawless.